Abraham Moris Korman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Abraham Moris Korman has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
Benjamin H. Kaffenberger
Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus, USA
7 shared publications- Benjamin Harris Kaffenberger
Department of Dermatology The Ohio State University Wexner Medical Center Columbus Ohio USA
7 shared publications Kristopher Fisher
Department of Dermatology The Ohio State University Wexner Medical Center Columbus Ohio USA
7 shared publications- Rachel M. Kirven
Department of Dermatology The Ohio State University Wexner Medical Center Columbus Ohio USA
7 shared publications Brittany Dulmage
Department of Dermatology The Ohio State University Wexner Medical Center Columbus Ohio USA
5 shared publicationsCatherine Chung
Department of Dermatology The Ohio State University Wexner Medical Center Columbus Ohio USA
5 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Wiley in JEADV Clinical Practice
Cutaneous Eruptions Associated With Tumour Infiltrating Lymphocyte Therapy: A Case Series
Tumour‐infiltrating lymphocyte (TIL) therapy is a newly emerged effective treatment for advanced melanoma refractory to immune checkpoint inhibitors; however, its cutaneous adverse effects remain uncharacterized. We present the first case series describing dermatologic adverse effects associated with TIL therapy for malignant melanoma in five patients. These patients were treated with varying TIL regimens in combination with interleukin‐2 (IL‐2). The cutaneous reactions, which developed within 3−30 days following therapy, were primarily exanthems and ranged from self‐limited vascular proliferations to high‐risk morbilliform eruptions with systemic involvement. Patients were managed with supportive care and topical corticosteroids, with escalation to intravenous immunoglobulin in cases of severe systemic involvement. Four of the patients did not require dose adjustment or interruption of TIL therapy. One patient did require cessation of TIL therapy due to hypotension requiring vasopressors and acute kidney injury. The pathogenesis of these reactions is hypothesized to involve systemic immune activation and cytokine release following the infusion of activated T cells, with a potential contributory role of concurrent IL‐2 administration. As TIL therapy gains broader clinical use, recognition of its cutaneous adverse effects is increasingly important. This case series provides novel clinical and histopathological insights into TIL‐associated cutaneous eruptions and underscores the need for early dermatologic evaluation and monitoring to optimize patient outcomes.
- 12 October 2026
- Published by Wiley in JEADV Clinical Practice
Open AccessCutaneous Eruptions Associated With Tumour Infiltrating Lymphocyte Therapy: A Case Series
Tumour‐infiltrating lymphocyte (TIL) therapy is a newly emerged effective treatment for advanced melanoma refractory to immune checkpoint inhibitors; however, its cutaneous adverse effects remain uncharacterized. We present the first case series describing dermatologic adverse effects associated with TIL therapy for malignant melanoma in five patients. These patients were treated with varying TIL regimens in combination with interleukin‐2 (IL‐2). The cutaneous reactions, which developed within 3−30 days following therapy, were primarily exanthems and ranged from self‐limited vascular proliferations to high‐risk morbilliform eruptions with systemic involvement. Patients were managed with supportive care and topical corticosteroids, with escalation to intravenous immunoglobulin in cases of severe systemic involvement. Four of the patients did not require dose adjustment or interruption of TIL therapy. One patient did require cessation of TIL therapy due to hypotension requiring vasopressors and acute kidney injury. The pathogenesis of these reactions is hypothesized to involve systemic immune activation and cytokine release following the infusion of activated T cells, with a potential contributory role of concurrent IL‐2 administration. As TIL therapy gains broader clinical use, recognition of its cutaneous adverse effects is increasingly important. This case series provides novel clinical and histopathological insights into TIL‐associated cutaneous eruptions and underscores the need for early dermatologic evaluation and monitoring to optimize patient outcomes.
- 23 September 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 469
Augmenting the diagnosis of cellulitis using image-based machine learning
- 23 September 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 469
Augmenting the diagnosis of cellulitis using image-based machine learning
- 20 September 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 437
Truncal lesions, age, and smoking distinguish IgA vasculitis from cutaneous small-vessel vasculitis
- 20 September 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 437
Truncal lesions, age, and smoking distinguish IgA vasculitis from cutaneous small-vessel vasculitis
- Open Access
- 29 July 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
Drug reaction with eosinophilia and systemic symptoms syndrome
- 29 July 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
Open AccessDrug reaction with eosinophilia and systemic symptoms syndrome
- 9 June 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (12) , 2610-2612
Attendance at a Post‐Discharge Dermatology Clinic Is Associated With Reduced Rehospitalization Risk for Primary Dermatologic Conditions
- 9 June 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (12) , 2610-2612
Attendance at a Post‐Discharge Dermatology Clinic Is Associated With Reduced Rehospitalization Risk for Primary Dermatologic Conditions
- Open Access
- 26 March 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (8) , 1713-1715
Radiology‐Dermatology Diagnostic Variation in Skin and Soft Tissue Infections: A Cohort Analysis
- 26 March 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (8) , 1713-1715
Open AccessRadiology‐Dermatology Diagnostic Variation in Skin and Soft Tissue Infections: A Cohort Analysis
- Top Cited PapersOpen Access
- 7 February 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 95 (2) , 474-484
Updates on the diagnosis, prognosis, and management of IgA vasculitis in adults: A narrative review
- 7 February 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 95 (2) , 474-484
Top Cited PapersOpen AccessUpdates on the diagnosis, prognosis, and management of IgA vasculitis in adults: A narrative review
- 21 November 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (5) , 1099-1101
Bispecific Antibody‐Associated Subacute Cutaneous Lupus Erythematosus: A Novel Autoimmune Complication in Cancer Immunotherapy
- 21 November 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (5) , 1099-1101
Bispecific Antibody‐Associated Subacute Cutaneous Lupus Erythematosus: A Novel Autoimmune Complication in Cancer Immunotherapy
- 16 November 2025
- Published by Springer Nature
- p. 111-137
Genital Neoplasms
- Open Access
- 14 October 2025
- Published by Wiley in JEADV Clinical Practice
- Vol. 5 (2) , 577-580
Health‐Related Quality of Life in Stevens‐Johnson Syndrome and Toxic Epidermal Necrolysis: A Qualitative Study
Background: Epidermal necrolysis (EN), including Stevens‐Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), are severe cutaneous drug reactions with high morbidity. However, the quality of life (QoL) impact during acute hospitalization is not well understood. Objectives: To explore the acute QoL experience of EN patients and identify key domains to inform future QoL assessment tools and improve care. Methods: Twelve patients with confirmed EN were interviewed using a standardized script. Diagnoses were supported by histopathology and validated scoring systems. Interviews were analyzed thematically using NVivo software. Thematic saturation was reached after nine interviews. Results: Six QoL domains emerged: difficulties with activities of daily living, severe cutaneous symptoms, changes in physical appearance, painful oral symptoms, mental health challenges (e.g., anxiety, low mood), and medical distrust. Trimethoprim‐sulfamethoxazole was the most common culprit drug. All patients received systemic corticosteroids. Conclusions: These findings lay the groundwork for the development and validation of targeted quality‐of‐life assessment tools and support the need for holistic inpatient care strategies tailored to the physical, emotional, and relational disruptions experienced by patients with acute EN.
- 14 October 2025
- Published by Wiley in JEADV Clinical Practice
- Vol. 5 (2) , 577-580
Open AccessHealth‐Related Quality of Life in Stevens‐Johnson Syndrome and Toxic Epidermal Necrolysis: A Qualitative Study
Background: Epidermal necrolysis (EN), including Stevens‐Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), are severe cutaneous drug reactions with high morbidity. However, the quality of life (QoL) impact during acute hospitalization is not well understood. Objectives: To explore the acute QoL experience of EN patients and identify key domains to inform future QoL assessment tools and improve care. Methods: Twelve patients with confirmed EN were interviewed using a standardized script. Diagnoses were supported by histopathology and validated scoring systems. Interviews were analyzed thematically using NVivo software. Thematic saturation was reached after nine interviews. Results: Six QoL domains emerged: difficulties with activities of daily living, severe cutaneous symptoms, changes in physical appearance, painful oral symptoms, mental health challenges (e.g., anxiety, low mood), and medical distrust. Trimethoprim‐sulfamethoxazole was the most common culprit drug. All patients received systemic corticosteroids. Conclusions: These findings lay the groundwork for the development and validation of targeted quality‐of‐life assessment tools and support the need for holistic inpatient care strategies tailored to the physical, emotional, and relational disruptions experienced by patients with acute EN.